1-4 of 4
Sergey I. Moiseev
Close
Sort by
Journal Articles

Assessment of Minimal Residual Disease (MRD) In Relapsed CLL Patients Treated with Fludarabine and Cyclophosphamide with or without Rituximab (REACH)

Annika Dufour, MD, S. K Bohlander, PhD, Karsten Spiekermann, MD, Stephanie Schneider, Jan Braess, MD, Purvi Kakadiya, Kirsten E Mundt, PhD, Helen Smith, Ming Lin, PhD, Martin Barrett, PhD, Deborah Hurst, MD, Anna Dmoszynska, MD, PhD, Isabelle Bence-Bruckler, MD, FRCPC, Boris V Afanasiev, MD, John Catalano, MBBS, FRACP, FRCPA, Marco Montillo, Christian H. Geisler, MD, Sergey I Moiseev, MD, Philippe Solal-Celigny, MD, Tadeusz Robak, Wolfgang Hiddemann, MD
Journal: Blood
Blood (2010) 116 (21): 1390.
https://doi.org/10.1182/blood.V116.21.1390.1390
Published: 2010
Journal Articles

Effect of FCGR2A and FCGR3A variants on CLL outcome

David Dornan, Olivia Spleiss, Ru-Fang Yeh, Guillemette Duchateau-Nguyen, Annika Dufour, Jianguo Zhi, Tadeusz Robak, Sergey I. Moiseev, Anna Dmoszynska, Philippe Solal-Celigny, Krzysztof Warzocha, Javier Loscertales, John Catalano, Boris V. Afanasiev, Loree Larratt, Viktor A. Rossiev, Isabelle Bence-Bruckler, Christian H. Geisler, Marco Montillo, Michael K. Wenger, Martin Weisser
Journal: Blood
Blood (2010) 116 (20): 4212–4222.
https://doi.org/10.1182/blood-2010-03-272765
Published: 2010
Journal Articles

FC-Gamma Receptor (FCGR) 2A and 3A Polymorphisms Do Not Influence the Outcome of Relapsed or Refractory CLL Patients Treated with Rituximab, Fludarabine, and Cyclophosphamide (R-FC) or Fludarabine, and Cyclophosphamide (FC) Alone.

David Dornan, Ph.D, Olivia Spleiss, Ph.D, Ru-Fang T Yeh, PhD, Guillemette Duchateau-Nguyen, PhD, Tadeusz Robak, Sergey I Moiseev, MD, Anna Dmoszynska, MD, Philippe Solal-Celigny, MD, Krzysztof Warzocha, MD, PhD, Javier Loscertales, MD, John Catalano, MD, Boris V Afanasiev, MD, Loree Larratt, MD, Viktor A Rossiev, MD, PhD, Isabelle Bence-Bruckler, MD, FRCPC, Christian H. Geisler, MD, DMSc, Marco Montillo, MD, Michael K. Wenger, MD, Martin Weisser, MD
Journal: Blood
Blood (2009) 114 (22): 2338.
https://doi.org/10.1182/blood.V114.22.2338.2338
Published: 2009
Journal Articles

Rituximab, Fludarabine, and Cyclophosphamide (R-FC) Prolongs Progression Free Survival in Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) Compared with FC Alone: Final Results from the International Randomized Phase III REACH Trial

Tadeusz Robak, MD, PhD, Sergey I Moiseev, MD, Anna Dmoszynska, MD, Philippe Solal-Céligny, MD, Krzysztof Warzocha, MD, PhD, Javier Loscertales, MD, John Catalano, MD, Boris V Afanasiev, MD, Loree Larratt, MD, Christian Geisler, MD, DMSc, Marco Montillo, MD, Peter Ganly, BMBCh, PhD, Caroline Dartigeas, MD, András Rosta, MD, PhD, Ann Janssens, MD, Myriam Mendila, MD, Jörg Maurer, Michael K. Wenger, MD
Journal: Blood
Blood (2008) 112 (11): lba-1.
https://doi.org/10.1182/blood.V112.11.lba-1.lba-1
Published: 2008